 ENGLEWOOD, Colo., Sept. 15, 2021 PRNewswire -- Ampio Pharmaceuticals NYSE American: AMPE, a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced top-line results from AP-013, a randomized, saline-controlled, double-blind Phase III clinical study evaluating the efficacy of an intra-articular IA injection of AmpionTM in adults with pain due to severe osteoarthritis of the knee OAK. 